• Alvotech recently reported that the FDA has closed its May 2026 inspection of the Reykjavik manufacturing facility with a Voluntary Action Indicated classification, confirming that the company’s corrective actions have addressed earlier observations and allowing it to keep advancing multiple Biologics License Applications in the US.
• This resolution, alongside the resubmission or acceptance of BLAs for biosimilars to Simponi, Eylea and Entyvio, strengthens the company’s regulatory footing in key high-value biologic markets.
• Next, we will examine how the FDA’s Voluntary Action Indicated outcome may influence Alvotech’s investment narrative and pipeline-driven outlook.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Alvotech Investment Narrative Recap

To own Alvotech, you need to believe it can turn its biosimilar pipeline into durable, cash-generating products while managing regulatory and balance sheet pressure. The FDA’s Voluntary Action Indicated outcome meaningfully reduces near term regulatory uncertainty around the Reykjavik plant, which helps the key catalyst of U.S. BLA decisions for AVT05, AVT06 and AVT16, but financing risk and high leverage still look like the biggest overhangs.

The most relevant recent announcement here is the FDA acceptance of the BLA for AVT16, Alvotech’s proposed biosimilar to Entyvio. With the Reykjavik inspection now closed as VAI, the same facility supports AVT16 alongside AVT05 and AVT06, tying this asset more firmly to the main regulatory catalyst set while still exposing investors to timing risk around approvals and eventual launch trajectories.

Yet behind this regulatory progress, investors should also be aware of the ongoing pressure that high debt and capital needs could place on…

Alvotech’s narrative projects $1.0 billion revenue and $223.4 million earnings by 2029.

Uncover how Alvotech's forecasts yield a $13.83 fair value, a 236% upside to its current price.

Exploring Other Perspectives

Some bullish analysts were expecting Alvotech to reach about US$1.2 billion in revenue and US$360.7 million in earnings by 2029, so this FDA update could either reinforce that optimistic view on regulatory risk or prompt a rethink of how quickly those targets might be reached.

Explore 5 other fair value estimates on Alvotech - why the stock might be worth just $4.00!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.

No Opportunity In Alvotech?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.